Astria Therapeutics, an emerging leader in biopharmaceuticals, distinguishes itself with strong finances, targeted drug development for unmet medical needs, a diverse pipeline, and patient-centric approaches, securing a robust market position.
This article discusses a new method for the selective bromination of indole alkaloids, focusing on the C5 position. The method is efficient and versatile, making it valuable for drug development.
